8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Jan 17, 2012)

Filed January 17, 2012For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has initiated legal action by filing a patent infringement complaint against Tekmira Pharmaceuticals Corporation in the U.S. District Court for the District of Massachusetts. The lawsuit centers on Tekmira's alleged infringement of several Alnylam-owned patents related to small interfering RNA (siRNA) and lipid nanoparticle (LNP) formulation technologies. Alnylam asserts that Tekmira's activities, specifically providing LNP-formulated siRNA molecules to a collaborator, are not covered by exemptions for drug development. The complaint, filed on January 17, 2012, seeks a judgment of infringement, a permanent injunction against Tekmira's activities, damages, and legal costs. Alnylam has also joined Isis Pharmaceuticals, Inc. as a co-plaintiff, as Alnylam holds contractual rights to enforce one of the patents (U.S. Patent No. 7,695,902) owned by Isis. This legal action is significant as it pertains to core technologies in Alnylam's RNA interference (RNAi) therapeutic development platform.

Key Highlights

  • 1Alnylam Pharmaceuticals filed a patent infringement lawsuit against Tekmira Pharmaceuticals on January 17, 2012.
  • 2The lawsuit alleges infringement of Alnylam's core siRNA and LNP formulation technologies.
  • 3Tekmira's activities providing LNP-formulated siRNA molecules to a collaborator are cited as infringing.
  • 4Alnylam claims Tekmira's activities are not protected by drug development exemptions.
  • 5The complaint seeks a permanent injunction, damages, and legal costs.
  • 6Isis Pharmaceuticals is joined as a co-plaintiff due to Alnylam's enforcement rights for a specific patent.

Frequently Asked Questions

Alnylam Pharmaceuticals has sued Tekmira Pharmaceuticals for patent infringement, alleging that Tekmira's activities involving the provision of lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) molecules to a third-party collaborator infringe upon Alnylam's intellectual property rights related to these core technologies.

Alnylam is seeking a court judgment confirming patent infringement, a permanent injunction to stop Tekmira's infringing activities, monetary damages, and reimbursement for legal costs and attorneys' fees.

Isis Pharmaceuticals is a co-plaintiff in the lawsuit because Alnylam Pharmaceuticals holds contractual rights to enforce U.S. Patent No. 7,695,902, which is owned by Isis. This allows Alnylam to pursue infringement claims on behalf of Isis for this specific patent.

This lawsuit is significant as it directly defends Alnylam's foundational intellectual property in siRNA and LNP formulation, which are critical to its development of RNA interference (RNAi) therapeutics. Protecting these patents is crucial for Alnylam's business and future commercialization efforts.